HomeCompareNUUU vs PFE

NUUU vs PFE: Dividend Comparison 2026

NUUU yields 2000000.00% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NUUU wins by $4.879226400974806e+39M in total portfolio value
10 years
NUUU
NUUU
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full NUUU calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — NUUU vs PFE

📍 NUUU pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNUUUPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NUUU + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NUUU pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NUUU
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, NUUU beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NUUU + PFE for your $10,000?

NUUU: 50%PFE: 50%
100% PFE50/50100% NUUU
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

NUUU
No analyst data
Altman Z
-67.9
Piotroski
3/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NUUU buys
0
PFE buys
0
No recent congressional trades found for NUUU or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNUUUPFE
Forward yield2000000.00%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$4.879226400974806e+39M$49.6K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$26,258.71
Total dividends collected$4.879195005460081e+39M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: NUUU vs PFE ($10,000, DRIP)

YearNUUU PortfolioNUUU Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$200,010,700$200,000,000.00$9,153$693.39+$200.00MNUUU
2$3,738,731,768,458$3,738,517,757,009.35$8,593$849.25+$3738731.76MNUUU
3$65,315,062,866,930,490$65,311,062,423,938,240.00$8,336$1,066.78+$65315062866.92MNUUU
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$8,437$1,384.80+$1066400830062625.00MNUUU
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$9,013$1,875.40+$16272182796453826560.00MNUUU
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$10,306$2,680.72+$2.3205424011366188e+23MNUUU
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$12,820$4,101.38+$3.0927990661046884e+27MNUUU
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$17,673$6,826.70+$3.8524105697352695e+31MNUUU
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$27,543$12,591.86+$4.484688260147987e+35MNUUU
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$49,560$26,258.71+$4.879226400974806e+39MNUUU

NUUU vs PFE: Complete Analysis 2026

NUUUStock

Rejuvel Bio-Sciences, Inc., a development stage company, produces, distributes, markets, and sells skin care products worldwide. The company primarily offers skin cream under the Rejuvel brand. It also intends to develop, build, and sell environmental management solutions that use electron particle accelerator technology for the treatment of drinking water, municipal and industrial wastewater, sludge, and produced water from oil and gas fracturing activities. The company was formerly known as Technology Applications International Corporation and changed its name to Rejuvel Bio-Sciences, Inc. in June 2015. Rejuvel Bio-Sciences, Inc. was founded in 2009 and is headquartered in Miami, Florida.

Full NUUU Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this NUUU vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NUUU vs SCHDNUUU vs JEPINUUU vs ONUUU vs KONUUU vs MAINNUUU vs JNJNUUU vs MRKNUUU vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.